Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
Want to see BRNS full AI Analyst Report?
Top Page
Barinthus Biotherapeutics
(NASDAQ:BRNS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.59
▼(-21.97% Downside)
Action:ReiteratedDate:04/30/26
The score is held down primarily by weak financial performance (unstable revenue, deep losses, and persistent cash burn), which implies ongoing financing risk. Technical indicators are broadly neutral, offering limited confirmation of a sustained uptrend. Corporate events add some support via the announced merger and leadership appointment, but do not fully offset the underlying cash flow and profitability challenges.
Positive Factors
Low leverage on balance sheet
Low absolute debt gives Barinthus structural financial flexibility versus highly leveraged peers. With modest debt levels, the company can prioritize financing operating needs, support clinical programs, or absorb short-term shocks without immediate pressure from interest or covenant constraints, aiding multi-quarter stability.
Negative Factors
Persistent negative operating cash flow
Consistent and deep negative operating and free cash flow indicate the business structurally consumes cash to fund R&D and operations. Over multiple quarters this forces reliance on external capital, increases dilution risk, and constrains discretionary investments absent sustained profitability or deal financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage on balance sheet
Low absolute debt gives Barinthus structural financial flexibility versus highly leveraged peers. With modest debt levels, the company can prioritize financing operating needs, support clinical programs, or absorb short-term shocks without immediate pressure from interest or covenant constraints, aiding multi-quarter stability.
Read all positive factors
Barinthus Biotherapeutics (BRNS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.58M
Dividend YieldN/A
Average Volume (3M)124.73K
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue Growth-100.00%
EPS Growth21.30%
CountryUS
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.04
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$7.00Price Target Upside821.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.29
Revenue Forecast (FY)N/A
Barinthus Biotherapeutics Business Overview & Revenue Model
Company Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeli...
How the Company Makes Money
null...
Barinthus Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 14.97M | 802.00K | 44.70M | 268.00K |
| Gross Profit | -1.76M | -5.86M | 14.97M | 802.00K | 44.70M | 268.00K |
| EBITDA | -49.32M | -48.34M | -55.37M | -71.06M | 5.19M | -47.87M |
| Net Income | -52.29M | -66.43M | -61.07M | -73.35M | 5.34M | -50.87M |
Balance Sheet | ||||||
| Total Assets | 92.14M | 98.17M | 160.33M | 214.51M | 270.20M | 280.71M |
| Cash, Cash Equivalents and Short-Term Investments | 67.19M | 70.46M | 110.66M | 142.09M | 194.38M | 214.05M |
| Total Debt | 11.01M | 11.28M | 12.01M | 12.98M | 8.77M | 7.22M |
| Total Liabilities | 25.66M | 23.88M | 30.19M | 27.51M | 27.00M | 28.15M |
| Stockholders Equity | 66.40M | 74.21M | 130.03M | 186.78M | 242.90M | 252.13M |
Cash Flow | ||||||
| Free Cash Flow | -36.43M | -48.02M | -29.83M | -56.34M | -20.57M | -33.73M |
| Operating Cash Flow | -36.40M | -47.98M | -28.94M | -50.92M | -14.43M | -32.58M |
| Investing Cash Flow | 475.48K | 416.00K | -892.00K | -5.41M | -5.75M | -12.91M |
| Financing Cash Flow | 0.00 | 2.00K | 2.16M | 1.87M | 325.00K | 222.74M |
Barinthus Biotherapeutics Technical Analysis
Neutral
0.76
Price Trends
0.60
Negative
0.66
Negative
0.95
Negative
Market Momentum
>-0.01
Negative
50.49
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRNS, the sentiment is Neutral. The current price of 0.76 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.60, and below the 200-day MA of 0.95, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.49 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BRNS.
Barinthus Biotherapeutics Risk Analysis
Barinthus Biotherapeutics disclosed 101 risk factors in its most recent earnings report. Barinthus Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Barinthus Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $35.20M | -0.46 | -49.73% | ― | ― | 11.59% | |
48 Neutral | $26.58M | -1.05 | -70.57% | ― | -100.00% | 21.30% | |
48 Neutral | $222.42M | -0.60 | -182.01% | ― | ― | 27.22% | |
45 Neutral | $37.68M | -1.22 | -28.16% | ― | -44.59% | 93.48% | |
44 Neutral | $11.52M | -2.93 | -42.29% | ― | 373.88% | -59.79% | |
42 Neutral | $5.92M | -1.49 | -92.74% | ― | 360.39% | 35.61% |
* Healthcare Sector Average
BRNS
Barinthus Biotherapeutics
0.65
-0.31
-32.29%
CLGN
Collplant Holdings
0.41
-1.69
-80.43%
ALXO
ALX Oncology Holdings
1.69
1.14
207.27%
ALGS
Aligos Therapeutics
6.09
1.04
20.59%
GDTC
CytoMed Therapeutics Limited
0.97
-1.42
-59.29%
BOLD
Boundless Bio Inc.
1.57
0.00
0.00%
Barinthus Biotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
Positive
Apr 22, 2026
On April 22, 2026, Barinthus Biotherapeutics plc announced that its board appointed industry veteran Douglas Swirsky as Chief Financial Officer and principal accounting officer, with the appointment becoming effective May 1, 2026. Swirsky brings m...
Business Operations and StrategyExecutive/Board Changes
Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change
Negative
Mar 31, 2026
Barinthus Biotherapeutics plc disclosed that Gemma Jones, who has been providing services as principal accounting officer through CFGI, will step down from her role. She notified the company on March 27, 2026, and her resignation will be effective...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Barinthus Bio Announces 2025 Results and Clywedog Merger
Positive
Mar 13, 2026
On March 13, 2026, Barinthus Bio reported full-year 2025 results, highlighted by a proposed all-stock merger with diabetes-focused Clywedog Therapeutics, expected to close in the second quarter of 2026 and create a combined Nasdaq-listed entity na...
Business Operations and StrategyM&A Transactions
Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms
Neutral
Feb 23, 2026
On September 29, 2025, Barinthus Biotherapeutics (Beacon) agreed to a complex cross-border combination under which newly formed Beacon Topco, Inc. would acquire Beacon via a U.K. scheme of arrangement, while Cdog Merger Sub, Inc. would merge with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.